XTL Biopharmaceuticals Ltd. Stock Nasdaq
Equities
XTLB
US98386D3070
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.6 USD | +0.39% | +0.39% | +157.40% |
04-29 | Top Premarket Gainers | MT |
03-21 | XTL Biopharmaceuticals Ltd. announced that it expects to receive $1.5 million in funding | CI |
Sales 2021 | - | Sales 2022 | - | Capitalization | 6.36M 8.74M |
---|---|---|---|---|---|
Net income 2021 | - 0 | Net income 2022 | -1M -1.37M | EV / Sales 2021 | - |
Net cash position 2021 | 6.13M 8.41M | Net cash position 2022 | 3.72M 5.11M | EV / Sales 2022 | - |
P/E ratio 2021 |
39.2
x | P/E ratio 2022 |
-4.72
x | Employees | 5 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 93.3% |
1 day | +0.39% | ||
1 week | +0.39% | ||
Current month | +0.39% | ||
1 month | -7.47% | ||
3 months | +196.91% | ||
6 months | +212.16% | ||
Current year | +157.40% |
Managers | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 98-12-31 |
Doron Turgeman
CHM | Chairman | 56 | 14-12-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 14-12-29 |
Director/Board Member | 57 | 20-01-28 | |
Director/Board Member | 53 | 17-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 2.6 | +0.39% | 9,177 |
24-04-30 | 2.59 | +7.02% | 21,356 |
24-04-29 | 2.42 | -0.08% | 5,292 |
24-04-26 | 2.422 | +0.92% | 5,253 |
24-04-25 | 2.4 | -6.25% | 6,198 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- XTLB Stock
- XTLB Stock